11:37 PM EST, 11/01/2026 (MT Newswires) -- Hutchmed's (China) (HCM.L) application for Orpathys combined with AstraZeneca's (AZN.L, AZN.ST) Tagrisso was accepted for regulatory review in Europe and Japan. The combination treatment is for patients with locally advanced or metastatic non-small cell lung cancer whose disease has progressed after EGFR-TKI therapy, according to a Monday release. The pharmaceutical company said the filings are supported by results from the Saffron phase 3 trial and follow its September submission to the US Food and Drug Administration.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.